PC
MCID: PRS040
MIFTS: 97

Prostate Cancer (PC)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Prostate Cancer

MalaCards integrated aliases for Prostate Cancer:

Name: Prostate Cancer 57 12 25 74 37 13 55 43 3 15 38 63
Prostate Carcinoma 12 25 55 15 17 72
Prostate Cancer, Familial 57 12 75 53 72
Prostate Neoplasm 12 25 29 6
Familial Prostate Cancer 53 59 29
Prostatic Neoplasms 55 44 72
Prostatic Cancer 12 25 15
Prostate Cancer, Susceptibility to 57 6
Malignant Neoplasm of Prostate 72 33
Malignant Tumor of Prostate 29 6
Hereditary Prostate Cancer 12 53
Prostate Cancer, Somatic 57 6
Prostatic Neoplasm 12 25
Prostate Cancer, Familial, Susceptibility to 57
Malignant Neoplasm of the Prostate 25
Malignant Tumor of the Prostate 12
Ngp - New Growth of Prostate 12
Prostate Cancer, Hereditary 53
Cancer of the Prostate 25
Tumor of the Prostate 12
Carcinoma of Prostate 12
Prostatic Carcinoma 25
Cancer of Prostate 12
Cancer, Prostate 40
Prca 74
Pc 74

Characteristics:

Orphanet epidemiological data:

59
familial prostate cancer
Prevalence: 1-9/100000 (United States); Age of onset: Adult;

OMIM:

57
Inheritance:
somatic mutation
autosomal dominant


HPO:

32
prostate cancer:
Inheritance autosomal dominant inheritance somatic mutation


Classifications:

Orphanet: 59  
Rare urogenital diseases


External Ids:

Disease Ontology 12 DOID:10283 DOID:10286
OMIM 57 176807
KEGG 37 H00024
ICD9CM 35 185
MeSH 44 D011471
SNOMED-CT 68 93974005
ICD10 33 C61
MESH via Orphanet 45 C537243
ICD10 via Orphanet 34 C61
UMLS via Orphanet 73 C2931456
Orphanet 59 ORPHA1331
MedGen 42 C0376358
UMLS 72 C0033578 C0376358 C0600139 more

Summaries for Prostate Cancer

Genetics Home Reference : 25 Prostate cancer is a common disease that affects men, usually in middle age or later. In this disorder, certain cells in the prostate become abnormal and multiply without control or order to form a tumor. The prostate is a gland that surrounds the male urethra and helps produce semen, the fluid that carries sperm. Early prostate cancer usually does not cause pain, and most affected men exhibit no noticeable symptoms. Men are often diagnosed as the result of health screenings, such as a blood test for a substance called prostate specific antigen (PSA) or a medical procedure called a digital rectal exam. As the tumor grows larger, signs and symptoms can include difficulty starting or stopping the flow of urine, a feeling of not being able to empty the bladder completely, blood in the urine or semen, or pain with ejaculation. However, these changes can also occur with many other genitourinary conditions. Having one or more of these symptoms does not necessarily mean that a man has prostate cancer. The severity and outcome of prostate cancer varies widely. Early-stage prostate cancer can usually be treated successfully, and some older men have prostate tumors that grow so slowly that they may never cause health problems during their lifetime, even without treatment. In other men, however, the cancer is much more aggressive; in these cases, prostate cancer can be life-threatening. Some cancerous tumors can invade surrounding tissue and spread to other parts of the body. Tumors that begin at one site and then spread to other areas of the body are called metastatic cancers. The signs and symptoms of metastatic cancer depend on where the disease has spread. If prostate cancer spreads, cancerous cells most often appear in the lymph nodes, bones, lungs, liver, or brain. Bone metastases of prostate cancer most often cause pain in the lower back, pelvis, or hips. A small percentage of all prostate cancers cluster in families. These hereditary cancers are associated with inherited gene mutations. Hereditary prostate cancers tend to develop earlier in life than non-inherited (sporadic) cases.

MalaCards based summary : Prostate Cancer, also known as prostate carcinoma, is related to hereditary breast ovarian cancer syndrome and prostate disease, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Prostate Cancer is CHEK2 (Checkpoint Kinase 2), and among its related pathways/superpathways are Prostate cancer and Transcriptional misregulation in cancer. The drugs Ofloxacin and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include prostate, prostate and bone, and related phenotypes are prostate cancer and cellular

Disease Ontology : 12 A male reproductive organ cancer that is located in the prostate.

NIH Rare Diseases : 53 Familial prostate cancer is a cluster of prostate cancer within a family. Most cases of prostate cancer occur sporadically in people with no family history of the condition. However, approximately 5% to 10% of prostate cancer cases are believed to be primarily caused by a genetic predisposition to the condition. In many families, the underlying genetic cause is unknown; however, some of these cases are caused by changes (mutations) in the BRCA1, BRCA2, HOXB13, or several other genes. Other cases are likely due to a combination of gene(s) and other shared factors such as environment and lifestyle. High-risk cancer screening at an earlier age is typically recommended in men who have an increased risk for prostate cancer based on personal and/or family histories.

MedlinePlus : 43 The prostate is the gland below a man's bladder that produces fluid for semen. Prostate cancer is common among older men. It is rare in men younger than 40. Risk factors for developing prostate cancer include being over 65 years of age, family history, and being African-American. Symptoms of prostate cancer may include Problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling Low back pain Pain with ejaculation To diagnose prostate cancer, you doctor may do a digital rectal exam to feel the prostate for lumps or anything unusual. You may also get a blood test for prostate-specific antigen (PSA). These tests are also used in prostate cancer screening, which looks for cancer before you have symptoms. If your results are abnormal, you may need more tests, such as an ultrasound, MRI, or biopsy. Treatment often depends on the stage of the cancer. How fast the cancer grows and how different it is from surrounding tissue helps determine the stage. Men with prostate cancer have many treatment options. The treatment that's best for one man may not be best for another. The options include watchful waiting, surgery, radiation therapy, hormone therapy, and chemotherapy. You may have a combination of treatments. NIH: National Cancer Institute

CDC : 3 Cancer is a disease in which cells in the body grow out of control. When cancer starts in the prostate, it is called prostate cancer. Not including skin cancer, prostate cancer is the most common cancer in American men.

KEGG : 37
Prostate cancer constitutes a major health problem in Western countries. It is the most frequently diagnosed cancer among men and the second leading cause of male cancer deaths. The identification of key molecular alterations in prostate-cancer cells implicates carcinogen defenses (GSTP1), growth-factor-signaling pathways (NKX3.1, PTEN, and p27), and androgens (AR) as critical determinants of the phenotype of prostate-cancer cells. Glutathione S-transferases (GSTP1) are detoxifying enzymes. Cells of prostatic intraepithelial neoplasia, devoid of GSTP1, undergo genomic damage mediated by carcinogens. NKX3.1, PTEN, and p27 regulate the growth and survival of prostate cells in the normal prostate. Inadequate levels of PTEN and NKX3.1 lead to a reduction in p27 levels and to increased proliferation and decreased apoptosis. Androgen receptor (AR) is a transcription factor that is normally activated by its androgen ligand. During androgen withdrawal therapy, the AR signal transduction pathway also could be activated by amplification of the AR gene, by AR gene mutations, or by altered activity of AR coactivators. Through these mechanisms, tumor cells lead to the emergence of androgen-independent prostate cancer.

Novus Biologicals : 56 Prostate cancer is the most common non-skin cancer and second most deadly cancer for men in the United States. Prostate cancer occurs when cells within the prostate grow uncontrollably and create small tumors. If untreated, cells from these tumors can spread via metastasis. Metastasis transports prostate cancer cells through the lymphatic system and bloodstream to other parts of the body where they can grow into secondary tumors. PSA, a protein produced by the prostate, is released into the bloodstream in small amounts under normal conditions. However, PSA is released in increasing amounts when the prostate is malfunctioning, as is the case with prostate cancer.

UniProtKB/Swiss-Prot : 74 Prostate cancer: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.

PubMed Health : 63 About prostate cancer: Prostate cancer develops when cells in the prostate start multiplying uncontrollably. This can happen if the genetic information (DNA) in the cells has changed (mutated). The body’s immune system usually keeps these cells in check. Cancer develops if too many mutated cells multiply and a tumor grows. The diagnosis “prostate cancer” usually comes as a shock to men and those close to them. The good news is that prostate cancer is one of the types of cancer with the best chances of recovery. This is because it often grows very slowly so it is generally possible to treat it effectively.

Wikipedia : 75 Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system.... more...

More information from OMIM: 176807

Related Diseases for Prostate Cancer

Diseases in the Prostate Cancer family:

Prostate Cancer, Hereditary, 1 Prostate Cancer, Hereditary, 8
Prostate Cancer, Hereditary, 3 Prostate Cancer, Hereditary, 4
Prostate Cancer, Hereditary, 5 Prostate Cancer, Hereditary, 6
Prostate Cancer, Hereditary, 7 Prostate Cancer, Hereditary, 9
Prostate Cancer, Hereditary, 10 Prostate Cancer, Hereditary, 12
Prostate Cancer, Hereditary, 13 Prostate Cancer, Hereditary, 11
Prostate Cancer, Hereditary, 14 Prostate Cancer, Hereditary, 15
Prostate Cancer, Hereditary, 2 Prostate Carcinoma in Situ

Diseases related to Prostate Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1347)
# Related Disease Score Top Affiliating Genes
1 hereditary breast ovarian cancer syndrome 34.6 TP53 PTEN CHEK2 BRCA2
2 prostate disease 34.5 TP53 PTEN AR
3 suppression of tumorigenicity 12 34.3 TP53 PTEN PIK3CA KLF6 CDH1 AR
4 breast cancer 34.2 TP53 PTEN PIK3CA MIR222 MIR221 MIR21
5 adenocarcinoma 33.8 TP53 PTEN PIK3CA CDH1
6 ovarian cancer 33.7 TP53 PTEN PIK3CA MIRLET7C MIR222 MIR221
7 bladder cancer 33.7 TP53 MIR222 MIR221 MIR21 MIR205 MIR145
8 colorectal cancer 33.6 TP53 PTEN PIK3CA MIR221 MIR21 MIR145
9 lung cancer 33.5 TP53 PTEN POLK PIK3CA MIRLET7C MIR222
10 hepatocellular carcinoma 33.3 TP53 PTEN PIK3CA MIRLET7C MIR222 MIR221
11 gastric cancer 33.1 TP53 PTEN PIK3CA MIR222 MIR221 MIR21
12 endometrial cancer 33.0 TP53 PTEN PIK3CA CDH1 BRCA2 AR
13 glioblastoma 33.0 TP53 PTEN PIK3CA MIR222 MIR221 MIR21
14 pancreatic cancer 33.0 TP53 PIK3CA MIR222 MIR221 MIR21 MIR205
15 esophageal cancer 32.9 TP53 PTEN PIK3CA MIR21 MIR205 CHEK2
16 glioblastoma multiforme 32.8 TP53 PTEN PIK3CA MIR221 MIR21
17 cervical cancer 32.7 TP53 PTEN PIK3CA MIRLET7C MIR21 CDH1
18 glioma 32.7 TP53 PTEN PIK3CA MIR222 MIR221 MIR21
19 squamous cell carcinoma 32.7 TP53 PTEN PIK3CA MIR205 CHEK2 CDH1
20 melanoma 32.6 TP53 PTEN MIR222 MIR221 MIR205
21 female breast cancer 32.5 TP53 BRCA2 AR
22 transitional cell carcinoma 32.4 TP53 PTEN CDH1
23 wilms tumor 1 32.4 TP53 CHEK2 BRCA2 AR
24 leukemia, acute myeloid 32.4 TP53 MIRLET7C MIR222 MIR221 MIR21 MIR146A
25 squamous cell carcinoma, head and neck 32.4 TP53 PTEN PIK3CA MIR221 MIR21 MIR205
26 kidney cancer 32.4 TP53 MIR21 MIR17
27 sporadic breast cancer 32.4 TP53 PTEN CHEK2 BRCA2
28 small cell cancer of the lung 32.4 TP53 PTEN PIK3CA MIR21
29 adenoid cystic carcinoma 32.3 TP53 PTEN PIK3CA CHEK2 CDH1
30 carcinosarcoma 32.3 TP53 PTEN PIK3CA
31 ductal carcinoma in situ 32.2 TP53 CDH1 BRCA2 AR
32 coronary heart disease 1 32.2 MIR222 MIR221 MIR17 MIR145
33 li-fraumeni syndrome 32.2 TP53 PTEN CHEK2 BRCA2
34 meningioma, familial 32.1 TP53 PTEN CDH1
35 large intestine cancer 32.1 TP53 PTEN PIK3CA CHEK2 CDH1
36 diffuse large b-cell lymphoma 32.1 TP53 MIR221 MIR21 MIR145
37 brain cancer 32.1 TP53 PTEN PIK3CA BRCA2
38 reproductive system disease 32.0 TP53 PTEN CDH1 BRCA2 AR
39 lung squamous cell carcinoma 31.9 TP53 PTEN PIK3CA CDH1
40 medulloblastoma 31.9 TP53 PTEN PIK3CA MIR17 BRCA2
41 dermatomyositis 31.9 MIR222 MIR221 MIR21
42 male reproductive organ cancer 31.9 TP53 PTEN CDH1 AR
43 cholangiocarcinoma 31.9 TP53 PTEN PIK3CA MIR21 CDH1
44 clear cell renal cell carcinoma 31.9 TP53 PTEN MIR21 MIR145 CDH1
45 leukemia, acute lymphoblastic 31.9 MIRLET7C MIR222 MIR221 MIR21
46 oral cancer 31.8 TP53 MIR21 CDH1
47 adenosquamous carcinoma 31.8 TP53 PIK3CA AR
48 testicular germ cell tumor 31.8 TP53 PTEN MIR145 AR
49 pancreatic ductal adenocarcinoma 31.7 MIR221 MIR21 MIR146A MIR145
50 li-fraumeni syndrome 2 31.7 TP53 CHEK2

Comorbidity relations with Prostate Cancer via Phenotypic Disease Network (PDN): (show all 34)


Acute Kidney Failure Anthracosis
Asbestosis Azoospermia
Balanoposthitis Bladder Cancer
Bladder Neck Obstruction Cystitis Cystica
Deficiency Anemia Disseminated Intravascular Coagulation
Epididymo-Orchitis Gout
Hydronephrosis Kidney Disease
Lipoma of Spermatic Cord Lymphadenitis
Nephrolithiasis, X-Linked Recessive, with Renal Failure Oligospermia
Paralytic Ileus Paraplegia
Prostate Calculus Prostate Carcinoma in Situ
Prostate Disease Prostatic Hypertrophy
Prostatitis Radiation Cystitis
Spermatocele Spinal Cord Disease
Ureterolithiasis Urethral Benign Neoplasm
Urethral Calculus Urethral Stricture
Urethritis Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Prostate Cancer:



Diseases related to Prostate Cancer

Symptoms & Phenotypes for Prostate Cancer

Human phenotypes related to Prostate Cancer:

32
# Description HPO Frequency HPO Source Accession
1 prostate cancer 32 HP:0012125

Symptoms via clinical synopsis from OMIM:

57
Neoplasia:
early onset prostate cancer

Clinical features from OMIM:

176807

UMLS symptoms related to Prostate Cancer:


tremor, angina pectoris, equilibration disorder

MGI Mouse Phenotypes related to Prostate Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10 AR BRCA2 CDH1 CHEK2 KLF6 MAD1L1
2 endocrine/exocrine gland MP:0005379 9.9 AR BRCA2 CDH1 CHEK2 KLF6 MAD1L1
3 neoplasm MP:0002006 9.65 AR BRCA2 CDH1 CHEK2 MAD1L1 MXI1
4 reproductive system MP:0005389 9.32 AR BRCA2 CDH1 KLF6 MAD1L1 MXI1

Drugs & Therapeutics for Prostate Cancer

PubMed Health treatment related to Prostate Cancer: 63

The possible treatment options for prostate cancer will depend on various factors. These include: how much the cells have changed (how aggressive the tumor is)how much the tumor has grown or spread (the stage of prostate cancer)the man’s PSA levelsindividual factors such as the man’s age, how healthy he is otherwise, and how important the pros and cons are to him. Men who have high-risk prostate cancer will usually have their prostate surgically removed or treatment with radiotherapy. Radiotherapy can be done in two ways: from outside of the body (external radiotherapy) or from inside the body (internal radiotherapy, or brachytherapy). The most common side effects of radiotherapy or removing the prostate gland are accidental leakage of urine (urinary incontinence) and erection problems (impotence). External radiotherapy is especially likely to cause diarrhea, and in some cases inflammations in the bowel which may result in blood in the stool and cramps. If the tumor is small, only inside the prostate, and not aggressive (low-risk prostate cancer), the following treatments are also possible: Active surveillance: Here the prostate cancer is simply monitored, and not treated, at first. This strategy is based on the fact that low-risk prostate cancer usually grows very slowly or doesn't grow at all. It is often found that the cancer has still not advanced even years after it was diagnosed. Instead of having treatment, the prostate is checked regularly. Treatment attempting to get rid of the cancer (curative treatment) is only started if the tumor starts growing. The advantage of this approach is that the side effects of surgery or radiotherapy can be avoided as long as the cancer does not grow. One possible disadvantage: If the cancer does progress, that is sometimes discovered too late. It may have already spread to other parts of the body by then (metastasis). Knowing that you have cancer in your body can be distressing too.Watchful waiting: This strategy also starts by only monitoring the prostate cancer at first. But if the tumor starts growing, only the symptoms are treated, not the tumor itself (this is known as “palliative care). This approach is mainly considered in older men, who may also have other medical problems. The risks and stress of surgery or radiotherapy could outweigh the possible benefits of this treatment. There is no “right” or “wrong” treatment decision for men who have low-risk prostate cancer. The strategy that one man chooses will mainly depend on his personal preferences and values. Some will feel it is more important to avoid side effects like impotence or incontinence as much as possible. Others will want to be very sure that the cancer has been removed, so they are willing to accept the risks associated with treatment. For more advanced stages of prostate cancer, there are several kinds of hormonal treatments and chemotherapies that aim to slow the growth.

DrugBank drugs 16 :

# Drug Name Indication DrugBank ID
1 Capromab pendetide For diagnosis of prostate cancer and detection of intra-pelvic metastases. DB00089
2 Choline C-11 Choline C 11 Injection is indicated for positron emission tomography (PET) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI). In these patients, 11 C-choline PET imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation. Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy. In clinical studies, imag es w ere produced with PET/CT coregistration. DB09563
3 Etoposide For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme. DB00773
4 Fluciclovine (18F) Fluciclovine is indicated as a detection agent for positron emission tomography (PET) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.[A31388] The overexpression of L-type amino acid transporters such as LAT1 and LAT3 that mediate the uptake of essential amino acids has been extensively reported as a tumoral mechanism of cell growth.[A31389] DB13146

Drugs for Prostate Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 925)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ofloxacin Approved Phase 4 82419-36-1 4583
2
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
3
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
4
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
5
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
6
Sodium citrate Approved, Investigational Phase 4 68-04-2
7
Nitric Oxide Approved Phase 4 10102-43-9 145068
8
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
9
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
10
Desflurane Approved Phase 4 57041-67-5 42113
11
Ondansetron Approved Phase 4 99614-02-5 4595
12
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
13
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
14
Chlorpheniramine Approved Phase 4 132-22-9, 113-92-8 2725
15
Prilocaine Approved Phase 4 721-50-6 4906
16
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
17
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
18
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
19
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
20
Polyestradiol phosphate Approved Phase 4 28014-46-2
21
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
22
Pasireotide Approved Phase 4 396091-73-9 9941444
23
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
24
Cabergoline Approved Phase 4 81409-90-7 54746
25
Zoledronic Acid Approved Phase 4 118072-93-8 68740
26
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
27
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
28
Remifentanil Approved Phase 4 132875-61-7 60815
29
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
30
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
31
Denosumab Approved Phase 4 615258-40-7
32
tannic acid Approved Phase 4 1401-55-4
33
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
34
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
35
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
36
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
37
Pamidronate Approved Phase 4 40391-99-9 4674
38
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
39
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
40
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
41
4-Aminopyridine Approved Phase 4 504-24-5 1727
42
leucovorin Approved Phase 4 58-05-9 143 6006
43
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
44
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
45
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
46
Sulfamethoxazole Approved Phase 4 723-46-6 5329
47
Fosfomycin Approved Phase 4 23155-02-4 446987
48
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
49
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
50
Methyltestosterone Approved Phase 4 58-18-4 6010

Interventional clinical trials:

(show top 50) (show all 4749)
# Name Status NCT ID Phase Drugs
1 Comparison of Health Related Quality of Life and Other Clinical Parameters Between ThinSeed™ and OncoSeed™ for Permanent Low Dose Rate Implantation in Localized Prostate Cancer Unknown status NCT01379742 Phase 4
2 Intermittent Vs Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer Unknown status NCT00293670 Phase 4 Goserelin (Zoladex)
3 Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer Unknown status NCT01352598 Phase 4
4 Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer Unknown status NCT02757365 Phase 4 aspirin;Levofloxacin
5 METformin And Longevity (METAL): A Window of Opportunity Study Investigating Biological Effects of Metformin in Localised Prostate Cancer Unknown status NCT02511665 Phase 4 Metformin;Placebo
6 MRI With a Lymph Node Specific Contrast Agent: an Alternative for CT-Scanning and Lymph Node Dissection in Patients With Prostate Cancer? Unknown status NCT00185029 Phase 4
7 Use of Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis, Prediction of Clinical Outcome and Monitoring of Treatment Response to Neoadjuvant Chemotherapy Unknown status NCT01956409 Phase 4 18F-FCH;Magnevist
8 To Investigate Post-procedure Hemorrhage and Cardiovascular Events in Taiwanese Patients Who Continue or Discontinue Low-Dose Aspirin Before Transrectal Prostate Biopsy: a Prospective Randomized Trial Unknown status NCT02744937 Phase 4 Aspirin
9 Nerve Grafting With an Allograft During Radical Prostatectomy - Extended Follow-up in a Prospective Randomized Trial Unknown status NCT01770340 Phase 4
10 The Effect of Testosterone Therapy on Angina Threshold and Atheroma in Patients With Chronic Stable Angina Unknown status NCT00131183 Phase 4 Nebido
11 Effect of Enteral Genistein Supplementation on Inflammatory Cytokines, Morbidity and Mortality in Patients With Sepsis Unknown status NCT02796794 Phase 4
12 A Randomised Pilot Study to Evaluate the Effect(s) of Casodex 150 mg and Zoladex 3.6 mg on Pathological and Genomic Tumour Markers in Subjects Undergoing Radical Prostatectomy for Localised Prostate Carcinoma Completed NCT00293696 Phase 4 bicalutamide (Casodex), goserelin (Zoladex)
13 A Multicenter, Open-label Study to Determine the Effect of iv. Zoledronic Acid on Pain and Quality of Life in Patients With Bone Metastases With or Without Skeletal Related Events (SRE) Resulting From Breast Cancer and Prostate Cancer Completed NCT00434317 Phase 4 Zoledronic acid
14 A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer Completed NCT00220194 Phase 4 leuprolide acetate
15 An Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis Completed NCT00035997 Phase 4 Zometa
16 Improving Prostate Biopsy Efficiency: The Finasteride Challenge Test Completed NCT01296672 Phase 4 Finasteride;Placebo
17 A Randomized, Open-label, Parallel-group Study, to Assess the Pharmocodynamic Effect on Dihydrotestosterone Regulated Gene Expression, Longitudinally and in a Dose Dependent Manner, of 0.5mg and 3.5mg Dutasteride Administered Orally Once Daily, for One Year in Men With Symptomatic Benign Prostatic Hyperplasia and During a Two Month Period Between Baseline and Radical Prostatectomy in Men With Biopsy-proven, Clinically Localized Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
18 Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer Completed NCT00219271 Phase 4 Zoledronic acid
19 Phase IV Study of Safety and Efficacy of Docetaxel in Combination With Prednisone in Advanced Hormone Refractory Prostate Cancer Treatment Completed NCT00280098 Phase 4 docetaxel
20 Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases Completed NCT00242554 Phase 4 Zoledronic acid
21 Non-comparative, Opened Multicenter Study to Assess the Efficacy and Safety of ELIGARD 22.5mg in the Treatment of Subjects With Prostate Cancer Completed NCT01511874 Phase 4 ELIGARD 22.5mg
22 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid
23 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4 Zoledronic acid
24 A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure Completed NCT01977651 Phase 4 Enzalutamide
25 A Multi-center, Single Arm Study of Enzalutamide in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate Completed NCT02116582 Phase 4 Enzalutamide
26 Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy. Completed NCT00237146 Phase 4 Zoledronic acid
27 A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates Completed NCT00172016 Phase 4 Zoledronic acid
28 Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer Completed NCT00391690 Phase 4 Zoledronic acid
29 Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases Completed NCT00219219 Phase 4 Zoledronic acid
30 An Open Randomised Trial to Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX Monotherapy Induced Gynaecomastia and/or Breast Pain in Prostate Cancer Patients Completed NCT00590213 Phase 4 Casodex 150mg
31 A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men Who Are Candidates for or Undergoing Expectant Management Completed NCT00363311 Phase 4 Dutasteride;Matching placebo
32 A Prospective, Single-arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis Completed NCT00334139 Phase 4 Zoledronic Acid
33 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin Completed NCT02102646 Phase 4 Triptorelin
34 Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer Completed NCT00199485 Phase 4 Angelica Sinensis
35 A 12 Month Open Label Study of Serum Testosterone Recovery and PSA After Neo-Adjuvant Treatment With Eligard(TM) 22.5mg Used With Radiation Therapy in Patients With Early Prostate Cancer Completed NCT01136226 Phase 4 Eligard (TM)
36 A Pilot Study on Endothelial Function and Cardiovascular Biomarkers in Prostate Cancer (PCa) Patients, With Pre-existing Cardiovascular Disease, Treated With Degarelix vs. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Completed NCT02475057 Phase 4 Degarelix (LHRH antagonist);LHRH agonist
37 Radical Prostatectomy and Perioperative Fluid Therapy Completed NCT00771966 Phase 4
38 A Randomized Double-Blind Parallel Group Study Comparing Casodex (or Generic Equivalent) 50mg Plus Placebo to Casodex (or Generic Equivalent) 50mg Plus Dutasteride 3.5mg Administered for 18 Months to Men With Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase Completed NCT00470834 Phase 4 dutasteride;placebo;bicalutamide
39 A Pilot Study to Assess the Technical Feasibility of Robotic Assisted Laparoscopic Interpositioning of the AVANCETM Nerve Graft for Reconstruction of the Neurovascular Bundle, With a Twenty-four Month Follow-up Term to Assess Efficacy Completed NCT00953277 Phase 4
40 Effect of Isoflavones on Cognition, Quality of Life and Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Completed NCT00245518 Phase 4 Isoflavone;Placebos
41 The Effect of Zoledronic Acid Compared to Placebo on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy Completed NCT00063609 Phase 4 zoledronic acid
42 Does Androgen Suppression Treatment In Prostate Cancer Reduce Myocardial Blood Flow Reserve? Completed NCT01230905 Phase 4
43 Multicentre, Single Arm, Open Label, Non Controlled Phase IV Clinical Trial to Evaluate Safety of Cabazitaxel (Jevtana) in Combination With Oral Prednisone (or Prednisolone) for the Treatment of Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen Completed NCT02074137 Phase 4 CABAZITAXEL XRP6258;Prednisone;Prednisolone
44 Randomized, Double-Blind, Placebo-Controlled Trial Assessing The Efficacy And Safety Of Dutasteride At Improving Lower Urinary Tract Symptoms In Men With Clinically Localized Prostate Cancer Being Treated With Single-Dose Goserelin, Trans-Urethral Incision Of Prostate, And Interval Brachytherapy Completed NCT00805701 Phase 4 avodart;Placebo
45 A Phase 4 Study of Zytiga in Poor-risk mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients Who Was Failed the First-line CAB (Combined Androgen Blockade) Therapy Completed NCT02405858 Phase 4 Abiraterone Acetate;Prednisolone
46 Randomized Crossover Trial to Assess the Tolerability of GnRH Analogue Administration in Patients With Advanced Prostate Cancer Completed NCT01161563 Phase 4 Triptorelin pamoate;Leuprolide acetate
47 The Effect Of Risedronate On Bone Turnover And Bone Mass In Older Men Completed NCT00859027 Phase 4 risedronate;Placebo risedronate oral tablet
48 Open Randomized Clinical Trial to Examine Individual Pain Tolerance in the Use of Two Anesthetic Techniques to Perform Saturation Prostate Biopsy Completed NCT02909049 Phase 4 MIDAZOLAM;MEPIVACAÍNE;FENTANILE;KETAMINE
49 The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide in Patients Undergoing Laparoscopic Surgery Completed NCT02149628 Phase 4 propofol;Desflurane
50 A Phase IV, Multicenter, National, Non-comparative, Open-label Study of Cabazitaxel, Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Second-line Treatment of Patients With Metastatic Castration-resistant Prostate Cancer and After Failure of Docetaxel-based Chemotherapy. Descriptive Assessment of the Circulating Tumor Cells in This Context. Completed NCT01649635 Phase 4 CABAZITAXEL (XRP6258);Prednisone;Ciprofloxacin;G-CSF (Granulocyte colony-stimulating factor)

Search NIH Clinical Center for Prostate Cancer

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Aminoglutethimide
bicalutamide
Capromab pendetide
Chlorotrianisene
Choline C-11
Cisplatin
CISPLATIN PWDR
Diethylstilbestrol
Estradiol
Estradiol acetate
estradiol cypionate
ESTRADIOL PWDR
estradiol valerate
Estramustine
Estramustine Phosphate Sodium
Estrogens
Estrogens, Conjugated (USP)
Estrogens, Esterified (USP)
Estrone
Ethinyl Estradiol
Etoposide
Etoposide
etoposide phosphate
Finasteride
Fluciclovine (18F)
Flutamide
fosfestrol
Goserelin Acetate
hydroxyurea
Leuprolide
Leuprolide Acetate
Mitoxantrone
Mitoxantrone Hydrochloride
nilutamide
polyestradiol
polyestradiol phosphate
Sodium estrone sulfate
synthetic conjugated estrogens, A
synthetic conjugated estrogens, B

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Prostate Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Prostate Cancer:
Alescat, autologous lymphocyte-based therapy for the treatment of solid cancers

Cochrane evidence based reviews: prostatic neoplasms

Genetic Tests for Prostate Cancer

Genetic tests related to Prostate Cancer:

# Genetic test Affiliating Genes
1 Familial Prostate Cancer 29
2 Malignant Tumor of Prostate 29 AR BRCA2 CDH1 CHEK2 KLF6 MAD1L1 MXI1 PTEN ZFHX3
3 Prostate Neoplasm 29

Anatomical Context for Prostate Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Prostate Cancer:

19
Prostate

MalaCards organs/tissues related to Prostate Cancer:

41
Prostate, Bone, Breast, Testes, Lymph Node, Lung, Endothelial

Publications for Prostate Cancer

Articles related to Prostate Cancer:

(show top 50) (show all 41295)
# Title Authors PMID Year
1
KLF6, a candidate tumor suppressor gene mutated in prostate cancer. 9 38 8 71
11752579 2001
2
Mutation of the MXI1 gene in prostate cancer. 9 38 8 71
7773287 1995
3
Multiple loci identified in a genome-wide association study of prostate cancer. 38 8 71
18264096 2008
4
Multiple newly identified loci associated with prostate cancer susceptibility. 38 8 71
18264097 2008
5
Comprehensive genetic evaluation of common E-cadherin sequence variants and prostate cancer risk: strong confirmation of functional promoter SNP. 9 8 71
16189707 2005
6
-160C/A polymorphism in the E-cadherin gene promoter and risk of hereditary, familial and sporadic prostate cancer. 9 8 71
14961571 2004
7
Induced chromosomal proximity and gene fusions in prostate cancer. 9 38 8
19933109 2009
8
Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. 9 38 71
12474142 2003
9
BRCA2 mutation in a family with hereditary prostate cancer. 9 38 71
11170288 2001
10
A candidate prostate cancer susceptibility gene at chromosome 17p. 9 38 71
11175785 2001
11
V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. 9 38 8
11164181 2001
12
IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. 38 8
29950727 2018
13
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. 38 8
28059768 2017
14
Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. 38 8
28059767 2017
15
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. 38 8
27433846 2016
16
Early detection of prostate cancer: AUA Guideline. 38 71
23659877 2013
17
The mutational landscape of lethal castration-resistant prostate cancer. 38 8
22722839 2012
18
Germline mutations in HOXB13 and prostate-cancer risk. 38 71
22236224 2012
19
The genomic complexity of primary human prostate cancer. 38 8
21307934 2011
20
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. 38 8
21289624 2011
21
Identification of a cell of origin for human prostate cancer. 38 8
20671189 2010
22
MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. 9 38 88
20332243 2010
23
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. 38 8
20220849 2010
24
Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. 38 8
19767754 2009
25
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. 38 8
19767753 2009
26
miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. 9 38 88
19584056 2009
27
Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. 9 71
19383797 2009
28
miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. 9 38 88
19252524 2009
29
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. 38 8
19212411 2009
30
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. 9 71
19042984 2008
31
Androgen receptor is a tumor suppressor and proliferator in prostate cancer. 38 8
18723679 2008
32
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. 38 71
18264098 2008
33
Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. 38 8
18187659 2008
34
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. 9 8
17637754 2008
35
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. 9 8
17671502 2007
36
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. 9 8
17377533 2007
37
A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. 9 71
17085682 2006
38
A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. 9 71
16155194 2006
39
Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. 9 71
16609730 2006
40
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. 9 8
16254181 2005
41
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. 38 8
15988677 2005
42
Global histone modification patterns predict risk of prostate cancer recurrence. 38 8
15988529 2005
43
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. 9 71
15750593 2005
44
CHEK2 is a multiorgan cancer susceptibility gene. 9 71
15492928 2004
45
Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2. 38 8
14560315 2004
46
Gene expression profiling identifies clinically relevant subtypes of prostate cancer. 38 8
14711987 2004
47
No association of germline alteration of MSR1 with prostate cancer risk. 9 71
12958598 2003
48
Genetic counseling for prostate cancer risk. 38 8
12694223 2003
49
Mutations in CHEK2 associated with prostate cancer risk. 38 71
12533788 2003
50
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. 9 71
12415269 2002